Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00186667 · ClinicalTrials.gov registry record · Phase 2
Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00186667: Completed Phase 2 study, sponsored by Stanford University.
NCT00186667 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00186667, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Evaluate the clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.
Interventions
- PROCEDURE high dose chemotherapy and autologous hematopoietic cell transplant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1999-01 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00186667
The ClinicalTrials.gov registry entry for NCT00186667 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which high dose chemotherapy and autologous hematopoietic cell transplant is the first listed.
NCT00186667 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00186667 about?
NCT00186667 is a clinical study titled "Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease". Evaluate the clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.
What is the current status of trial NCT00186667?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1999-01. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00186667?
The interventions under investigation include: high dose chemotherapy and autologous hematopoietic cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00186667?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.